# Anna Turetsky

> Anna Turetsky is a seed investor at OUP (Osage University Partners) backing Biopharma. See 3 investments, check sizes, portfolio and contact details. Updated…

- Type: Angel Investor
- Fund: [OUP (Osage University Partners)](https://shizune.co/investors/profile/osage-university-partners)
- Location: Boston, United States
- Total investments: 3
- Last investment: May 2021
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/anna-turetsky-50480338/
- Website: https://x.com/pannasea
- Facebook: https://www.facebook.com/profile.php?id=617007

Anna Turetsky is a seed investor at OUP (Osage University Partners) in Boston focused on Biopharma and Health Care. Anna Turetsky is based out of New York, New York, and is the General Partner of PxB Fund of OUP (Osage University Partners). Anna previously worked at Vicinitas Therapeutics as a Board Observer. Anna Turetsky attended University of Pennsylvania.

## Contacts

5 contacts available for Anna Turetsky: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/anna-turetsky?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biopharma | 1 | 33% |
| Health Care | 1 | 33% |
| Therapeutics | 1 | 33% |
| Biotechnology | 1 | 33% |
| Pharmaceutical | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 33% |
| Series A | 1 | 33% |
| Funding Round | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Interius BioTherapeutics | Interius BioTherapeutics is a biopharmaceutical company that targets cancer. The company spun out the University of Pennsylvania and is targeting cancer. | $76M | Series A | May 18, 2021 |  |
| Interius BioTherapeutics | Interius BioTherapeutics is a biopharmaceutical company that targets cancer. The company spun out the University of Pennsylvania and is targeting cancer. | $5.5M |  | Mar 13, 2020 |  |
| Interius BioTherapeutics | Interius BioTherapeutics is a biopharmaceutical company that targets cancer. The company spun out the University of Pennsylvania and is targeting cancer. | $5.5M | Seed | Mar 13, 2020 |  |

3 of 3 investments shown.

## Co-investors
- [Agent Capital](https://shizune.co/investors/profile/agent-capital) — VC Fund, 3 deals together
- [Penn Medicine Co-Investment Program](https://shizune.co/investors/profile/penn-medicine-co-investment-fund) — VC Fund, 3 deals together
- Tellus BioVentures — VC Fund, 3 deals together
- [Bain Capital Life Sciences](https://shizune.co/investors/profile/bain-capital-life-sciences) — VC Fund, 1 deal together
- [BrightEdge Fund](https://shizune.co/investors/profile/brightedge-fund) — VC Fund, 1 deal together
- [Cormorant Asset Management](https://shizune.co/investors/profile/cormorant-asset-management) — VC Fund, 1 deal together

## About OUP (Osage University Partners)

VC Fund · Bala Cynwyd, United States

Osage University Partners is a venture capital firm focused on investing in startups that are commercializing university technologies. Osage partners with research universities to invest in their innovative startups shareing its investment profit with partner institutions. The firm invests in software, hardware, and life science companies at allstages of company development. To date, it has partnered with over 80 universities, including 36 of the top 50 U.S. institutions by research expenditures, and has invested in over 50 of their spinouts.

5 contacts available at OUP (Osage University Partners).

| Name | Title | Profile |
| --- | --- | --- |
| Anna Turetsky | General Partner of PxB Fund | — |
| Beth Grafstrom | Vice President of Finance | — |
| Kirsten Leute | Partner, University Relations | — |
| Louis Berneman | Founding Partner | — |
| Marc Singer | Managing Partner | https://shizune.co/investors/profile/marc-singer |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Anna Turetsky invest in?

Anna Turetsky invests primarily in Biopharma, Health Care and Therapeutics startups, most often at Seed and Series A stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Anna Turetsky?

Public channels for Anna Turetsky include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Anna Turetsky last invest?

The most recent investment recorded for Anna Turetsky closed in May 2021. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co